OBJECTIVES: Although transcatheter aortic valve implantation (TAVI) is effective and less invasive than surgery, its superiority in terms of costs and quality of life is controversial and has not been well demonstrated in “real life” patients. The primary objective of the TEVAS study is to evaluate cost-utility of TAVI vs conventional surgery and conservative treatment. In this preliminary analysis we present clinical results, resource use, and changes in quality of life during the first month after TAVI in a real life setting. METHODS: Candidate patients were recruited prospectively at the time of indication in 7 Spanish hospitals. A centralized follow-up was performed by phone one month after intervention. We measured utility with EQ5D and specific quality of life with the Heart-QoL questionnaire. RESULTS: A total of 109 patients were recruited in the TAVI group and follow-up at one month was available for 66. Mean age: 80.8 (SD:6.6), mean logistic EuroSCORE: 14 (SD:12.6) (median:10.32, Q1-Q3:6.2-18.6). Four patients (6%) had severe complications after TAVI (AMI, stroke or need for a second valve) and 8 (12.1%) died in the first 30 days after TAVI. Among survivors, EQ5D score improved significantly from baseline (0.61, SD:0.33 to 0.72, SD:0.31; p-value:0.01) and so did the Heart-QoL overall score (1.44, SD:0.77 to 2.07, SD:0.58; p-value<0.001). During the first month of follow-up there were a mean of 0.89 visits per patient to the family physician, 0.40 to a specialist and 0.44 to the nurse. Six patients (10.3%) had at least one readmission (7% for cardiovascular causes; mean hospital length of stay: 6.8 days per patient). CONCLUSIONS: Although quality of life improves substantially in the first month after TAVI, in preliminary analysis resource use still remains high.